Log in

NASDAQ:MDWDMediwound Stock Price, Forecast & News

$2.05
+0.01 (+0.49 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.03
Now: $2.05
$2.07
50-Day Range
$1.65
MA: $1.96
$2.09
52-Week Range
$1.44
Now: $2.05
$4.65
Volume89,436 shs
Average Volume77,503 shs
Market Capitalization$55.77 million
P/E Ratio8.54
Dividend YieldN/A
Beta1.41
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Read More
Mediwound logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.60 out of 5 stars


Industry, Sector and Symbol

Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MDWD
CUSIPN/A
Phone972-8932-4010

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$31.79 million
Cash Flow$0.12 per share
Book Value$0.56 per share

Profitability

Net Income$4.95 million

Miscellaneous

Employees73
Market Cap$55.77 million
Next Earnings Date8/11/2020 (Estimated)
OptionableNot Optionable

Receive MDWD News and Ratings via Email

Sign-up to receive the latest news and ratings for MDWD and its competitors with MarketBeat's FREE daily newsletter.

Mediwound (NASDAQ:MDWD) Frequently Asked Questions

How has Mediwound's stock been impacted by COVID-19 (Coronavirus)?

Mediwound's stock was trading at $2.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MDWD shares have decreased by 11.3% and is now trading at $2.05. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Mediwound?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mediwound in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Mediwound.

When is Mediwound's next earnings date?

Mediwound is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020. View our earnings forecast for Mediwound.

How were Mediwound's earnings last quarter?

Mediwound Ltd (NASDAQ:MDWD) released its quarterly earnings results on Wednesday, May, 20th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.05. The biopharmaceutical company earned $4.44 million during the quarter, compared to analyst estimates of $4.25 million. Mediwound had a net margin of 18.46% and a negative return on equity of 75.91%. View Mediwound's earnings history.

What price target have analysts set for MDWD?

2 brokerages have issued 1-year price objectives for Mediwound's shares. Their forecasts range from $5.50 to $7.00. On average, they anticipate Mediwound's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 204.9% from the stock's current price. View analysts' price targets for Mediwound.

Has Mediwound been receiving favorable news coverage?

News coverage about MDWD stock has been trending very negative on Thursday, according to InfoTrie Sentiment. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mediwound earned a coverage optimism score of -3.1 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutMediwound.

Are investors shorting Mediwound?

Mediwound saw a decrease in short interest in May. As of May 15th, there was short interest totaling 104,100 shares, a decrease of 13.4% from the April 30th total of 120,200 shares. Based on an average daily volume of 55,400 shares, the days-to-cover ratio is presently 1.9 days. Approximately 0.7% of the shares of the company are sold short. View Mediwound's Current Options Chain.

Who are some of Mediwound's key competitors?

What other stocks do shareholders of Mediwound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mediwound investors own include Opko Health (OPK), Blackstone Group (BX), Mastercard (MA), Wells Fargo & Co (WFC), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Novavax (NVAX), Sorrento Therapeutics (SRNE), Alibaba Group (BABA) and Chubb (CB).

Who are Mediwound's key executives?

Mediwound's management team includes the following people:
  • Mr. Gal Cohen, Pres & CEO (Age 46)
  • Prof. Lior Rosenberg, Co-Founder & Chief Medical Technology Officer (Age 73)
  • Mr. Sharon Malka CPA, MBA, Chief Financial & Operation Officer (Age 47)
  • Mr. Carsten Henke, Chief Commercial Officer of Europe (Age 53)
  • Dr. Ety Klinger, Chief R&D Officer (Age 57)

What is Mediwound's stock symbol?

Mediwound trades on the NASDAQ under the ticker symbol "MDWD."

Who are Mediwound's major shareholders?

Mediwound's stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (8.88%), Wells Fargo & Company MN (0.81%), BOKF NA (0.76%), Acadian Asset Management LLC (0.48%), Sargent Investment Group LLC (0.43%) and Harel Insurance Investments & Financial Services Ltd. (0.37%).

Which institutional investors are selling Mediwound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Harel Insurance Investments & Financial Services Ltd., Wellington Management Group LLP, BOKF NA, and Morgan Stanley.

Which institutional investors are buying Mediwound stock?

MDWD stock was bought by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Fortis Advisors LLC, Sargent Investment Group LLC, and Wells Fargo & Company MN.

How do I buy shares of Mediwound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Mediwound's stock price today?

One share of MDWD stock can currently be purchased for approximately $2.05.

How big of a company is Mediwound?

Mediwound has a market capitalization of $55.77 million and generates $31.79 million in revenue each year. The biopharmaceutical company earns $4.95 million in net income (profit) each year or $0.08 on an earnings per share basis. Mediwound employs 73 workers across the globe.

What is Mediwound's official website?

The official website for Mediwound is www.mediwound.com.

How can I contact Mediwound?

Mediwound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972-8932-4010 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.